Bristol's New Chief Scientific Officer Lists Oncology Priorities, But Little New
Executive Summary
At ASCO, Bristol-Myers-Squibb's new Chief Scientific Officer Thomas Lynch highlighted key R&D priorities for advancing the company's cancer pipeline and staying ahead of its competitors.
You may also be interested in...
Is BMS The Must Have Immuno-Oncology Accessory Of The Season?
Bristol-Myers Squibb is in the M&A hot seat, and Pfizer could be the one applying fire.
Biomarker-Led Claim Is Small Step For Merck's Keytruda, Giant Leap For Cancer Indications
Accelerated approval for patients with microsatellite instability-high or mismatch repair deficient solid tumors is the first time the US FDA has granted an indication that does not specify the location of the tumor – a change precision medicine researchers have been eager to make.
AstraZeneca's Imfinzi Steals March Into Untapped IO Lung Cancer Territory
While most eyes were on AstraZeneca's keenly awaited MYSTIC lung cancer study of Imfinzi, its PACIFIC trial has ducked under the radar and hit investors with the nicest kind of surprise. The results could have wider implications for IO in earlier-stage cancers.